Cytek Biosciences, Inc. (CTKB) research
Cytek Biosciences, Inc.- Sector
- Life Sciences Tools & Services
- Last price
- $5.30
- As of
Cytek Biosciences, Inc. (CTKB): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-24.
As of . Source: SEC EDGAR filings for CTKB. Method and limitations.
Share the CTKB intelligence card
See CTKB live in the terminal
Track CTKB's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CTKB terminal, freeActive signals for CTKB
- highCONSENSUS_BUY
4 tracked funds increased CTKB this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased CTKB this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +270% to CTKB (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +346% to CTKB (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +157% to CTKB (2026Q2)
FREE, NO ACCOUNT
Every signal on CTKB, as it fires
You are seeing 5 of 27 signals recorded on CTKB since 2026-05-16.
The five above landed across 2 days. The other 22 were recorded on 5 other days. 15 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CTKB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 23285D109 · 2026Q2 | $41.4M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 23285D109 · 2026Q2 | $3.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 23285D109 · 2026Q2 | $3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 23285D109 · 2026Q2 | $2.9M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 23285D109 · 2026Q2 | $1.9M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 23285D109 · 2026Q2 | $745K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CTKB
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CTKB against its peers
CTKB's operating margin of -20.0% ranks in the 52nd percentile of 19 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-12-27 and 2026-06-30.
| Metric | CTKB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 201M USD | 460M USD | 40 | 20 |
| Gross margin | 51.8% | 53.3% | 50 | 10 |
| Operating margin | -20.0% | -20.6% | 53 | 19 |
| Net margin | -33.0% | -20.4% | 45 | 20 |
| Return on equity | -19.5% | -19.7% | 50 | 20 |
| P / E | n/a | 71.6x | n/a | 5 |
Peers (20): MLAB, OABI, DNA, MRVI, PACB, FTRE, CDXS, ABCL, MXCT, ADPT, SEER, SHC, BRKR, RGEN, TXG, AVTR, TEM, TECH, CRL, MEDP. Fiscal periods ending between 2025-12-27 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CTKB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CTKB signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CTKBand get the insider, 13F, options, and confluence read in one view.